Advertisement

Topics

MannKind Company Profile

14:22 EDT 19th June 2018 | BioPortfolio

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a proprietary dry powder formulation of Technosphere® insulin that is inhaled into the deep lung using our proprietary MedTone® inhaler. The inhaler is light, easy to use, and fits in the palm of the patient's hand, which is believed to facilitate patient compliance. We believe that the performance characteristics, unique kinetics, convenience and ease of use of the Technosphere® Insulin System may have the potential to change the way diabetes is treated. In particular, we have observed in our clinical trials to date that the Technosphere® Insulin System produces a profile of insulin levels in the bloodstream that approximates the insulin profile normally seen in healthy individuals immediately following the beginning of a meal, but which is absent in all patients with diabetes. As a result, we believe that our Technosphere Insulin System will be beneficial not only for insulin-using diabetes patients but also for patients with type 2 diabetes who are currently using conventional therapies other than insulin. If further clinical trials support our initial observations, we believe the Technosphere Insulin System has the potential to be indicated for the treatment of type 2 diabetes after a patient has failed to respond adequately to diet and exercise. The use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease.

Location

28903 North Avenue Paine
Valencia
California
91355
United States of America

Contact

Phone: (661) 775-5300


News Articles [82 Associated News Articles listed on BioPortfolio]

MannKind nets $26.6mm via RDO

MannKind Corp. netted $26.6mm through a registered direct offering of 14mm common shares at $2 each (a 16% discount) to institutional investors. The company also issued warrants to buy up to another 1...

MannKind Names Lilly Exec as New CMO

He will be based out of MannKind’s Westlake Village, California headquarters.

Deals this week: MannKind, XtalPi, Ascendia Pharmaceuticals

Indian biopharmaceutical company MannKind has agreed to sign a marketing and distribution agreement with Cipla for the inhaled insulin drug,...Read More... The post Deals this week: MannKind, XtalPi, ...

Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague

MannKind could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today.

Cipla gets Indian rights to MannKind's Afrezza

MannKind Corp. licensed Cipla Ltd. exclusive rights to market and distribute the Type I and II diabetes drug Afrezza (insulin) inhalation powder in India.

MannKind Co. (MNKD) Short Interest Up 4.4% in January

MannKind Co. was the target of a large increase in short interest in the month of January.

MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere

MannKind (Nasdaq:MNKD) announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administr...

Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?

Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether...   

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its ...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product c...

MannKind Corporation and Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has use...

More Information about "MannKind" on BioPortfolio

We have published hundreds of MannKind news stories on BioPortfolio along with dozens of MannKind Clinical Trials and PubMed Articles about MannKind for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MannKind Companies in our database. You can also find out about relevant MannKind Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record